Mining the pathways of Aging

We are a pharmaceutical company focused on the discovery, development and commercialization of pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. Our scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and we are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease. Metabolic diseases, including our primary targets of type 2 diabetes and obesity, constitute important global pharmaceutical markets in terms of size, growth and unmet medical need. Obesity rates are on the rise not only in the U.S. but also around the world, and are contributing to a worldwide epidemic of type 2 diabetes. Despite the high prevalence, expected growth, and injurious health consequences of these diseases, there are relatively few satisfactory therapeutic options available.

[ back to top ]